Parthenolide eliminates leukemia-initiating cell populations and improves survival in xenografts of childhood acute lymphoblastic leukemia
Published 2012 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Parthenolide eliminates leukemia-initiating cell populations and improves survival in xenografts of childhood acute lymphoblastic leukemia
Authors
Keywords
-
Journal
BLOOD
Volume 121, Issue 8, Pages 1384-1393
Publisher
American Society of Hematology
Online
2012-12-22
DOI
10.1182/blood-2012-08-448852
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Coexistence of LMPP-like and GMP-like Leukemia Stem Cells in Acute Myeloid Leukemia
- (2011) Nicolas Goardon et al. CANCER CELL
- Biology, Risk Stratification, and Therapy of Pediatric Acute Leukemias: An Update
- (2011) Ching-Hon Pui et al. JOURNAL OF CLINICAL ONCOLOGY
- Comparison of childhood leukemia initiating cell populations in NOD/SCID and NSG mice
- (2011) P Diamanti et al. LEUKEMIA
- Targeted inhibition of mTORC1 and mTORC2 by active-site mTOR inhibitors has cytotoxic effects in T-cell acute lymphoblastic leukemia
- (2011) C Evangelisti et al. LEUKEMIA
- Expression of CD34 and CD7 on human T-cell acute lymphoblastic leukemia discriminates functionally heterogeneous cell populations
- (2011) B Gerby et al. LEUKEMIA
- Evolution of human BCR–ABL1 lymphoblastic leukaemia-initiating cells
- (2011) Faiyaz Notta et al. NATURE
- Leukemia-initiating cells in human T-lymphoblastic leukemia exhibit glucocorticoid resistance
- (2010) P. P. L. Chiu et al. BLOOD
- Chemical genomic screening reveals synergism between parthenolide and inhibitors of the PI-3 kinase and mTOR pathways
- (2010) D. C. Hassane et al. BLOOD
- The mammalian target of rapamycin inhibitor RAD001 (everolimus) synergizes with chemotherapeutic agents, ionizing radiation and proteasome inhibitors in pre-B acute lymphocytic leukemia
- (2010) P. Saunders et al. HAEMATOLOGICA
- Parthenolide treatment activates stress signaling proteins in high-risk acute lymphoblastic leukemia cells with chromosomal translocation t(4;11)
- (2010) Zunino INTERNATIONAL JOURNAL OF ONCOLOGY
- Myeloperoxidase Expression as a Potential Determinant of Parthenolide-Induced Apoptosis in Leukemia Bulk and Leukemia Stem Cells
- (2010) Y. R. Kim et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
- Genetic variegation of clonal architecture and propagating cells in leukaemia
- (2010) Kristina Anderson et al. NATURE
- Phase I study of bortezomib combined with chemotherapy in children with relapsed childhood acute lymphoblastic leukemia (ALL): A report from the therapeutic advances in childhood leukemia (TACL) consortium
- (2010) Yoav Messinger et al. PEDIATRIC BLOOD & CANCER
- Potentiating effects of RAD001 (Everolimus) on vincristine therapy in childhood acute lymphoblastic leukemia
- (2009) R. Crazzolara et al. BLOOD
- Expression of CD133 on leukemia-initiating cells in childhood ALL
- (2009) C. V. Cox et al. BLOOD
- A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: a genome-wide classification study
- (2009) Monique L Den Boer et al. LANCET ONCOLOGY
- The NF- B subunit Rel A is associated with in vitro survival and clinical disease progression in chronic lymphocytic leukemia and represents a promising therapeutic target
- (2008) S. Hewamana et al. BLOOD
- Stem cell concepts renew cancer research
- (2008) J. E. Dick BLOOD
- In Childhood Acute Lymphoblastic Leukemia, Blasts at Different Stages of Immunophenotypic Maturation Have Stem Cell Properties
- (2008) Christoph le Viseur et al. CANCER CELL
- Acute lymphoblastic leukaemia
- (2008) Ching-Hon Pui et al. LANCET
- Bone-marrow relapse in paediatric acute lymphoblastic leukaemia
- (2008) L Charles Bailey et al. LANCET ONCOLOGY
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started